Year All2026202520242023202220212020201920182017201620152014 Mar 03, 2021 Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results Feb 23, 2021 Soleno Therapeutics Announces Collaboration with Vanderbilt University to Discover and Develop Next Generation K(ATP) Channel Activators for the Treatment of Rare Diseases Feb 05, 2021 Soleno Therapeutics Provides Recap of Key Opinion Leader Webinar on DCCR for Treatment of Prader-Willi Syndrome Jan 28, 2021 Soleno Therapeutics to Host Key Opinion Leader Meeting on DCCR for the Treatment of Prader-Willi Syndrome Jan 04, 2021 Soleno Therapeutics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference Dec 11, 2020 Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome Nov 10, 2020 Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2020 Financial Results Nov 03, 2020 Soleno Therapeutics Announces Presentation of Body Composition Results from DESTINY PWS, a Phase III Trial of DCCR in Prader-Willi Syndrome Oct 29, 2020 Soleno Therapeutics Announces Late-Breaking Oral Presentation with Body Composition Results from Phase III DESTINY PWS Trial of DCCR in Prader-Willi Syndrome at ObesityWeek® 2020 Meeting Sep 30, 2020 Soleno Therapeutics Announces Updated Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome
Mar 03, 2021 Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results
Feb 23, 2021 Soleno Therapeutics Announces Collaboration with Vanderbilt University to Discover and Develop Next Generation K(ATP) Channel Activators for the Treatment of Rare Diseases
Feb 05, 2021 Soleno Therapeutics Provides Recap of Key Opinion Leader Webinar on DCCR for Treatment of Prader-Willi Syndrome
Jan 28, 2021 Soleno Therapeutics to Host Key Opinion Leader Meeting on DCCR for the Treatment of Prader-Willi Syndrome
Jan 04, 2021 Soleno Therapeutics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference
Dec 11, 2020 Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
Nov 10, 2020 Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2020 Financial Results
Nov 03, 2020 Soleno Therapeutics Announces Presentation of Body Composition Results from DESTINY PWS, a Phase III Trial of DCCR in Prader-Willi Syndrome
Oct 29, 2020 Soleno Therapeutics Announces Late-Breaking Oral Presentation with Body Composition Results from Phase III DESTINY PWS Trial of DCCR in Prader-Willi Syndrome at ObesityWeek® 2020 Meeting
Sep 30, 2020 Soleno Therapeutics Announces Updated Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome